Evidence map›Paper›PMID 18762202›Full record

ArticleNeuropharmacology2009

Towards a quantitative representation of the cell signaling mechanisms of hallucinogens: measurement and mathematical modeling of 5-HT1A and 5-HT2A receptor-mediated ERK1/2 activation.

Chiung-Wen Chang, Ethan Poteet, John A Schetz, Zeynep H Gümüş, Harel Weinstein

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection.Investigative ophthalmology & visual science · 2018
    Article
  6. Toward a multiscale modeling framework for understanding serotonergic function.Journal of psychopharmacology (Oxford, England) · 2017
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chiung-Wen ChangDepartment of Physiology and Biophysics, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA.
Ethan Poteet
John A Schetz
Zeynep H Gümüş
Harel Weinstein
Cornell University · USUniversity of North Texas Health Science Center · US

Funding

HALLUCINOGENS IN SPECIFIC SIGNALING AND CIRCUITRYP01DA012923 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI WEINSTEIN, HAREL · 2000 to 2011
$8.6M
Neuroleptic Spacer Length Governs Molecular RecognitionR01MH063162 · NIMH · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SCHETZ, JOHN A · 2003 to 2009
$1.7M
NIDA NIH HHS P01 DA012923NIMH NIH HHS R01 MH063162
6 · The paper itself

Abstract

Through a multidisciplinary approach involving experimental and computational studies, we address quantitative aspects of signaling mechanisms triggered in the cell by the receptor targets of hallucinogenic drugs, the serotonin 5-HT2A receptors. To reveal the properties of the signaling pathways, and the way in which responses elicited through these receptors alone and in combination with other serotonin receptors' subtypes (the 5-HT1AR), we developed a detailed mathematical model of receptor-mediated ERK1/2 activation in cells expressing the 5-HT1A and 5-HT2A subtypes individually, and together. In parallel, we measured experimentally the activation of ERK1/2 by the action of selective agonists on these receptors expressed in HEK293 cells. We show here that the 5-HT1AR agonist Xaliproden HCl elicited transient activation of ERK1/2 by phosphorylation, whereas 5-HT2AR activation by TCB-2 led to higher, and more sustained responses. The 5-HT2AR response dominated the MAPK signaling pathway when co-expressed with 5-HT1AR, and diminution of the response by the 5-HT2AR antagonist Ketanserin could not be rescued by the 5-HT1AR agonist. Computational simulations produced qualitative results in good agreement with these experimental data, and parameter optimization made this agreement quantitative. In silico simulation experiments suggest that the deletion of the positive regulators PKC in the 5-HT2AR pathway, or PLA2 in the combined 5-HT1A/2AR model greatly decreased the basal level of active ERK1/2. Deletion of negative regulators of MKP and PP2A in 5-HT1AR and 5-HT2AR models was found to have even stronger effects. Under various parameter sets, simulation results implied that the extent of constitutive activity in a particular tissue and the specific drug efficacy properties may determine the distinct dynamics of the 5-HT receptor-mediated ERK1/2 activation pathways. Thus, the mathematical models are useful exploratory tools in the ongoing efforts to establish a mechanistic understanding and an experimentally testable representation of hallucinogen-specific signaling in the cellular machinery, and can be refined with quantitative, function-related information.

Indexed as

Models, BiologicalCell Line, TransformedComputer SimulationDose-Response Relationship, DrugExtracellular Signal-Regulated MAP KinasesHallucinogensHumansProtein BindingRadioligand AssayReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2ASignal TransductionTime FactorsTransfectionExtracellular Signal-Regulated MAP KinasesHallucinogensReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT2A

Identifiers

PMID18762202
PMCPMC2635340
OpenAlexW2129507956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.